News

Study findings demonstrate encouraging feasibility and initial acceptability of implementing an EHR-integrated symptom and needs screening and referral system among diverse oncology patients.

The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.

Patients with CLL or SLL who discontinued venetoclax as first-line therapy were older and had a greater disease burden and risk of tumor lysis syndrome when compared with those patients who completed at least 12 cycles of treatment, according...

Study findings suggest that neither olaparib monotherapy or olaparib plus cediranib increased progression-free survival when compared with platinum-based chemotherapy in women with high-grade serous or endometroid ovarian cancer sensitive to...

Avelumab and atezolizumab may have limited impact on the clinical outcome of patients with newly diagnosed ovarian carcinoma, according to recent study findings.

Among participants in a screening protocol for adjuvant clinical trials for resected early-stage NSCLC, only about half underwent adequate lymph node dissection and received adjuvant chemotherapy, despite guideline indications.

Study findings shed light on survival outcomes among vulnerable groups of pre-treated patients with advanced NSCLC receiving immunotherapy, who are often excluded from real-world clinical trials.

Findings from a cost-effectiveness analysis demonstrate that there is significant cost associated with the use of 3 years of adjuvant osimertinib for patients with resected EGFR-mutant NSCLC.

Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though

A population-based cohort analysis on patients who were diagnosed with mantle cell lymphoma found that overall survival and lymphoma-specific survival may improve with BTK inhibitors.